Why Theravance Shareholders Can Breathe Easier

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Theravance (UNKNOWN: THRX.DL  ) , a biopharmaceutical company focused on central nervous system and respiratory disorders, jumped as much as 14% after the Food and Drug Administration approved it and GlaxoSmithKline's (NYSE: GSK  ) revolutionary inhaled COPD treatment Breo Ellipta.

So what: Announced midday, the FDA approval confirms the generally positive opinion that the FDA's panel had of Breo Ellipta that it reduced flare-ups and helped air flow in patients with COPD. The approval will necessitate a $30 million milestone payment to GlaxoSmithKline from Theravance, but clears the drug for commercial production as of the third quarter of this year.

Now what: An approval here seemed like all but a formality with the once-daily inhaled compound performing well in trials and providing a well-tolerated safety profile. Peak sales estimates of the drug range all over the place, but I see no reason it won't reach blockbuster status (in excess of $1 billion). Furthermore, with Theravance planning to split itself into two entities, I'd be honestly shocked not to see Glaxo make a bid for the Royal Management segment with Breo Ellipta now approved. Theravance is still an intriguing name moving forward.

Craving more input? Start by adding Theravance to your free and personalized watchlist so you can keep up on the latest news with the company.

While you can certainly make huge gains in biotechs like Theravance, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2423960, ~/Articles/ArticleHandler.aspx, 9/30/2016 11:48:02 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 2 hours ago Sponsored by:
DOW 18,308.15 164.70 0.91%
S&P 500 2,168.27 17.14 0.80%
NASD 5,312.00 42.85 0.81%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/30/2016 4:02 PM
GSK $43.13 Up +0.23 +0.54%
GlaxoSmithKline CAPS Rating: ***
THRX.DL $0.00 Down +0.00 +0.00%
Theravance CAPS Rating: **